Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity
LF Valladales-Restrepo… - Expert Opinion on …, 2023 - Taylor & Francis
Background To determine the effectiveness, persistence of use, adverse reactions,
interactions of orlistat and liraglutide taken for weight loss by a group of obese patients in …
interactions of orlistat and liraglutide taken for weight loss by a group of obese patients in …
Use of liraglutide 3.0 mg for weight management in a real-world setting in Switzerland
CL Haase, MG Serratore Achenbach, G Lucrezi… - Obesity Facts, 2021 - karger.com
Introduction: Data from randomized controlled trials show that liraglutide 3.0 mg, in
combination with diet and exercise, is associated with greater weight loss than diet and …
combination with diet and exercise, is associated with greater weight loss than diet and …
Five-year weight loss maintenance with obesity pharmacotherapy
MA Weintraub, D D'Angelo, BG Tchang… - The Journal of …, 2023 - academic.oup.com
Context Long-term treatment of obesity with lifestyle changes alone is unsustainable for
most individuals because of several factors including adherence and metabolic adaptation …
most individuals because of several factors including adherence and metabolic adaptation …
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
S Wharton, CL Haase, E Kamran, A Liu… - Obesity Science & …, 2020 - Wiley Online Library
Objective Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical
trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes …
trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes …
[PDF][PDF] Obésité de l'adulte: prise en charge de 2e et 3e niveaux
I PARTIE - has-sante.fr
Obésité de l’adulte : prise en charge de 2e et 3e niveaux Page 1 RECOMMANDER LES
BONNES PRATIQUES ARGUMENTAIRE Obésité de l’adulte : prise en charge de 2e et 3e …
BONNES PRATIQUES ARGUMENTAIRE Obésité de l’adulte : prise en charge de 2e et 3e …
Weight changes following antidiabetic mediation use: Real‐world evidence from health system data
Objective Newer antidiabetic medications such as sodium‐glucose co‐transporter 2
inhibitors (SGLT2i) and glucagon‐like peptide 1 receptor agonists (GLP1RA) result in weight …
inhibitors (SGLT2i) and glucagon‐like peptide 1 receptor agonists (GLP1RA) result in weight …
[引用][C] Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
CLHMG Serratore, AGLNJ Susanne, MU Egermanne - 2021